UroGen Pharma Ltd. - Special Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the UroGen Pharma conference call. It is now my pleasure to turn the call over to Kate Bechtold, Senior Director of Investor Relations for UroGen Pharma. Please go ahead.
Thank you, operator, and welcome to the UroGen Pharma conference call to discuss the FDA approval of UroGen's lead product, UGN-101. Yesterday, we issued a press release highlighting this event. The press release can be accessed on the investors portion of our website at investors.urogen.com.
Joining me on the call today are Liz Barrett, President and Chief Executive Officer; Dr. Mark Schoenberg, Chief Medical Officer; and Jeff Bova, Chief Commercial Officer. Joining us for the Q&A portion of this call will be Peter Pfreundschuh, Chief Financial Officer.
As a reminder, during today's call, we will be making certain forward-looking statements. Various remarks that we make during this call about the company's future expectations, plans and prospects constitute forward-looking statements for
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
